MannKind is contractually obligated to pay various bills totaling $179 million in 2015, according to its annual report filed with the Securities and Exchange Commission. The biggest outlay is the $100 million convertible debt due in August, but the company must also spend $39 million for good and services related to Afrezza manufacturing and $28 million for insulin supply purchases via a contract with Amphastar ( AMPH ), according to the company's annual report.